Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CALC CalciMedica Inc
- Stocks
- Healthcare
- NASDAQ: CALC
Price (delayed)
$2
Market cap
$27.94M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.56
Enterprise value
$23.99M
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102,
Highlights
The EPS has contracted by 28% from the previous quarter but it has grown by 27% YoY
The quick ratio has grown by 9% from the previous quarter but it has contracted by 8% YoY
CALC's net income is down by 38% QoQ and by 26% YoY
CALC's equity is down by 37% year-on-year and by 24% since the previous quarter
Key stats
What are the main financial stats of CALC
Market
Valuations
Earnings
Shares outstanding
13.97M
Market cap
$27.94M
Enterprise value
$23.99M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.48
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$24.93M
Net income
-$18.87M
EBIT
-$18.43M
EBITDA
-$18.37M
Free cash flow
-$21.33M
Per share
Balance sheet
Liquidity
EPS
-$1.56
EPS diluted
-$1.56
Free cash flow per share
-$1.51
Book value per share
$0.81
Revenue per share
$0
TBVPS
$1.79
Total assets
$25.35M
Total liabilities
$14.46M
Debt
$8.6M
Equity
$10.89M
Working capital
$20.76M
Debt to equity
0.79
Current ratio
5.66
Quick ratio
5.52
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-91.6%
Return on equity
-156.7%
Return on invested capital
-182.1%
Return on capital employed
-88.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CALC stock price
How has the CalciMedica stock price performed over time
Intraday
3.09%
1 week
0%
1 month
29.87%
1 year
-63.17%
YTD
-43.5%
QTD
4.71%
Financial performance
How have CalciMedica's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.93M
Net income
-$18.87M
Gross margin
N/A
Net margin
N/A
CALC's net income is down by 38% QoQ and by 26% YoY
CALC's operating income is down by 16% year-on-year and by 3% since the previous quarter
Price vs fundamentals
How does CALC's price correlate with its fundamentals
Growth
What is CalciMedica's growth rate over time
Valuation
What is CalciMedica stock price valuation
P/E
N/A
P/B
2.48
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 28% from the previous quarter but it has grown by 27% YoY
CALC's equity is down by 37% year-on-year and by 24% since the previous quarter
CALC's price to book (P/B) is 29% lower than its last 4 quarters average of 3.5 but 24% higher than its 5-year quarterly average of 2.0
Efficiency
How efficient is CalciMedica business performance
The return on equity has dropped by 56% since the previous quarter and by 41% year-on-year
The ROIC has soared by 50% YoY but it has contracted by 32% from the previous quarter
CalciMedica's return on assets has decreased by 41% QoQ and by 16% YoY
Dividends
What is CALC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CALC.
Financial health
How did CalciMedica financials performed over time
The total assets is 75% greater than the total liabilities
The company's total liabilities has surged by 169% QoQ and by 46% YoY
The total assets has grown by 28% since the previous quarter but it has declined by 7% year-on-year
The debt is 21% smaller than the equity
CALC's equity is down by 37% year-on-year and by 24% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.